A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2014 Planned End Date changed from 1 Nov 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov.